Design Considerations for a Phase II Platform Trial in Major Depressive Disorder
Pharmaceutical Statistics · 2025-09 · 24 (5)
DOI: 10.1002/pst.70025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 27.08.2025. Verfasst von Michaela Maria Freitag und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universit…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Research Design, Clinical Trials, Phase II as Topic, Antidepressive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU-PEARL (EU Patient-cEntric clinicAl tRial pLatforms) project has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU), German Research Foundation, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Major depressive disorder (MDD) is one of the leading causes of disability globally. Despite its prevalence, approximately one‐third of patients do not benefit sufficiently from available treatments, and few new drugs have been developed recently. Consequently, more efficient methods are needed to evaluate a broader range of treatment options quickly. Platform trials offer a promising solution, as they allow for the assessment of multiple investigational treatments simultaneously by sharing control groups and by reducing both trial activation and patient recruitment times. The objective of this simulation study was to support the design and optimisation of a phase II superiority platform trial for MDD, considering the disease‐specific characteristics. In particular, we assessed the efficiency of platform trials compared to traditional two‐arm trials by investigating key design elements, including allocation and randomisation strategies, as well as per‐treatment arm sample sizes and interim futility analyses. Through extensive simulations, we refined these design components and evaluated their impact on trial performance. The results demonstrated that platform trials not only enhance efficiency but also achieve higher statistical power in evaluating individual treatments compared to conventional trials. The efficiency of platform trials is particularly prominent when interim futility analyses are performed to eliminate treatments that have either no or a negligible treatment effect early. Overall, this work provides valuable insights into the design of platform trials in the superiority setting and underscores their potential to accelerate therapy development in MDD and other therapeutic areas, providing a flexible and powerful alternative to traditional trial designs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
- Institute for Medical Biometry, Informatics and Epidemiology, Faculty of Medicine, University of Bonn, Bonn, Germany.
- Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.
- Berry Consultants, Vienna, Austria.
- Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
- Medical Department, Section Psychosomatics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
ORCID-Profile: Michaela Maria Freitag, Dario Zocholl, Elias Laurin Meyer, Stefan M Gold, Marta Bofill Roig, Martin Posch, Franz König
Förderung
- EU-PEARL (EU Patient-cEntric clinicAl tRial pLatforms) project has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU)
- German Research Foundation
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Freitag, M. M., Zocholl, D., Meyer, E. L., Gold, S. M., Roig, M. B., De Smedt, H., Posch, M., König, F., & EU‐PEARL MDD Investigators (2025). Design Considerations for a Phase II Platform Trial in Major Depressive Disorder. Pharmaceutical Statistics, 24(5). https://doi.org/10.1002/pst.70025
Vancouver
Freitag MM, Zocholl D, Meyer EL, Gold SM, Roig MB, De Smedt H, et al. Design Considerations for a Phase II Platform Trial in Major Depressive Disorder. Pharmaceutical Statistics. 2025;24(5). doi:10.1002/pst.70025
BibTeX
@article{Freitag2025,
author = {Freitag, Michaela Maria and Zocholl, Dario and Meyer, Elias Laurin and Gold, Stefan M and Roig, Marta Bofill and De Smedt, Heidi and Posch, Martin and König, Franz and EU‐PEARL MDD Investigators, EU‐PEARL MDD Investigators},
title = {Design Considerations for a Phase II Platform Trial in Major Depressive Disorder},
journal = {Pharmaceutical Statistics},
year = {2025},
volume = {24},
number = {5},
doi = {10.1002/pst.70025}
}
EUVIMED